Zobrazeno 1 - 10
of 334
pro vyhledávání: '"Fasan O"'
Autor:
Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina. Electronic address: michael.grunwald@atriumhealth.org., Sha W; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, 28204., He J; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland., Sanikommu S; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Gerber JM; Department of Medicine, Division of Hematology & Medical Oncology, New York University Grossman School of Medicine, New York, New York., Ai J; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Knight TG; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Fasan O; GLPG US, Princeton, New Jersey., Boseman V; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Kaizen W; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Chojecki A; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Ragon BK; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Symanowski J; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, 28204., Avalos B; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Copelan E; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep 26. Date of Electronic Publication: 2024 Sep 26.
Autor:
Morschhauser F; Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France. franck.morschhauser@chu-lille.fr., Dahiya S; Stanford University School of Medicine, Stanford, CA, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Martin Garcia-Sancho A; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain., Reguera Ortega JL; Hospital Virgen del Rocío, Instituto de Biomedicina de la Universidad de Sevilla, Seville, Spain., Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Jäger U; Medical University of Vienna, Vienna, Austria., Cartron G; Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France., Izutsu K; National Cancer Center Hospital, Tokyo, Japan., Dreyling M; LMU University Hospital, München, Germany., Kahl B; Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Ghesquieres H; Hôpital Lyon Sud, Lyon, France., Ardeshna K; University College London Hospitals Biomedical Research Centre, London, UK., Goto H; Hokkaido University Hospital, Sapporo, Japan., Barbui AM; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Abramson JS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Borchmann P; Universität zu Köln, Köln, Germany., Fleury I; Hôpital Maisonneuve - Rosemont, Montreal, Quebec, Canada., Mielke S; Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden., Skarbnik A; Novant Health Cancer Institute, Charlotte, NC, USA., de Vos S; UCLA Santa Monica Medical Centre, Santa Monica, CA, USA., Kamdar M; University of Colorado Cancer Center, Aurora, CO, USA., Karmali R; Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA., Viardot A; Department of Internal Medicine III, University Hospital, Ulm, Germany., Farazi T; Bristol Myers Squibb, Brisbane, CA, USA., Fasan O; Bristol Myers Squibb, Princeton, NJ, USA., Lymp J; Bristol Myers Squibb, Seattle, WA, USA., Vedal M; Bristol Myers Squibb, Seattle, WA, USA., Nishii R; Bristol Myers Squibb, Princeton, NJ, USA., Avilion A; Bristol Myers Squibb, Seattle, WA, USA., Papuga J; Bristol Myers Squibb, Boudry, Switzerland., Kumar J; Bristol Myers Squibb, Princeton, NJ, USA., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2374.
Autor:
Morschhauser F; Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France. franck.morschhauser@chu-lille.fr., Dahiya S; Stanford University School of Medicine, Stanford, CA, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Martin Garcia-Sancho A; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain., Reguera Ortega JL; Hospital Virgen del Rocío, Instituto de Biomedicina de la Universidad de Sevilla, Seville, Spain., Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Jäger U; Medical University of Vienna, Vienna, Austria., Cartron G; Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France., Izutsu K; National Cancer Center Hospital, Tokyo, Japan., Dreyling M; LMU University Hospital, München, Germany., Kahl B; Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Ghesquieres H; Hôpital Lyon Sud, Lyon, France., Ardeshna K; University College London Hospitals Biomedical Research Centre, London, UK., Goto H; Hokkaido University Hospital, Sapporo, Japan., Barbui AM; Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Abramson JS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Borchmann P; Universität zu Köln, Köln, Germany., Fleury I; Hôpital Maisonneuve - Rosemont, Montreal, Quebec, Canada., Mielke S; Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden., Skarbnik A; Novant Health Cancer Institute, Charlotte, NC, USA., de Vos S; UCLA Santa Monica Medical Centre, Santa Monica, CA, USA., Kamdar M; University of Colorado Cancer Center, Aurora, CO, USA., Karmali R; Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA., Viardot A; Department of Internal Medicine III, University Hospital, Ulm, Germany., Farazi T; Bristol Myers Squibb, Brisbane, CA, USA., Fasan O; Bristol Myers Squibb, Princeton, NJ, USA., Lymp J; Bristol Myers Squibb, Seattle, WA, USA., Vedal M; Bristol Myers Squibb, Seattle, WA, USA., Nishii R; Bristol Myers Squibb, Princeton, NJ, USA., Avilion A; Bristol Myers Squibb, Seattle, WA, USA., Papuga J; Bristol Myers Squibb, Boudry, Switzerland., Kumar J; Bristol Myers Squibb, Princeton, NJ, USA., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2199-2207. Date of Electronic Publication: 2024 Jun 03.
Publikováno v:
Cancer Management and Research, Vol 2015, Iss default, Pp 105-119 (2015)
Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administrat
Externí odkaz:
https://doaj.org/article/ecf9c4e6550343df8075637b542990c8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sanikommu SR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Reese ES; Department of Translational Science, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., He J; Department of Cancer Biostatistics, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Lee C; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Ai J; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Butler CM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Jacobs R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Hu B; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Atrash S; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Trivedi J; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Bhutani M; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Voorhees P; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Usmani SZ; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Fasan O; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Druhan LJ; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Symanowski J; Department of Cancer Biostatistics, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Copelan EA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA., Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA.
Publikováno v:
Journal of clinical apheresis [J Clin Apher] 2021 Aug; Vol. 36 (4), pp. 553-562. Date of Electronic Publication: 2021 Mar 12.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Journal of Cystic Fibrosis June 2020 19 Supplement 2:S158-S159
Autor:
Fasan O; Hematology, Transplantation and Cellular Therapy, Novant Health, Charlotte, North Carolina, USA.
Publikováno v:
Current opinion in hematology [Curr Opin Hematol] 2019 Nov; Vol. 26 (6), pp. 413-420.
Autor:
Kast, Richard E.1 (AUTHOR) richarderickast@gmail.com
Publikováno v:
Cells (2073-4409). Jul2024, Vol. 13 Issue 14, p1175. 16p.